196 related articles for article (PubMed ID: 38221546)
1. ALKBH5 is a prognostic factor and promotes the angiogenesis of glioblastoma.
Fan Y; Yan D; Ma L; Liu X; Luo G; Hu Y; Kou X
Sci Rep; 2024 Jan; 14(1):1303. PubMed ID: 38221546
[TBL] [Abstract][Full Text] [Related]
2. Loss of m6A demethylase ALKBH5 promotes post-ischemic angiogenesis via post-transcriptional stabilization of WNT5A.
Zhao Y; Hu J; Sun X; Yang K; Yang L; Kong L; Zhang B; Li F; Li C; Shi B; Hu K; Sun A; Ge J
Clin Transl Med; 2021 May; 11(5):e402. PubMed ID: 34047466
[TBL] [Abstract][Full Text] [Related]
3. High expression of AlkB homolog 5 suppresses the progression of non-small cell lung cancer by facilitating ferroptosis through m6A demethylation of SLC7A11.
Huang Z; Lin G; Hong Y; Weng L; Zhu K; Zhuang W
Environ Toxicol; 2024 Jul; 39(7):4035-4046. PubMed ID: 38642004
[TBL] [Abstract][Full Text] [Related]
4. The RNA demethylase ALKBH5 promotes the progression and angiogenesis of lung cancer by regulating the stability of the LncRNA PVT1.
Shen W; Pu J; Zuo Z; Gu S; Sun J; Tan B; Wang L; Cheng J; Zuo Y
Cancer Cell Int; 2022 Nov; 22(1):353. PubMed ID: 36376862
[TBL] [Abstract][Full Text] [Related]
5. RNA demethylase ALKBH5 prevents pancreatic cancer progression by posttranscriptional activation of PER1 in an m6A-YTHDF2-dependent manner.
Guo X; Li K; Jiang W; Hu Y; Xiao W; Huang Y; Feng Y; Pan Q; Wan R
Mol Cancer; 2020 May; 19(1):91. PubMed ID: 32429928
[TBL] [Abstract][Full Text] [Related]
6. m
Zhang S; Zhao BS; Zhou A; Lin K; Zheng S; Lu Z; Chen Y; Sulman EP; Xie K; Bögler O; Majumder S; He C; Huang S
Cancer Cell; 2017 Apr; 31(4):591-606.e6. PubMed ID: 28344040
[TBL] [Abstract][Full Text] [Related]
7. ALKBH5 Facilitates Hypoxia-Induced Paraspeckle Assembly and IL8 Secretion to Generate an Immunosuppressive Tumor Microenvironment.
Dong F; Qin X; Wang B; Li Q; Hu J; Cheng X; Guo D; Cheng F; Fang C; Tan Y; Yan H; He Y; Sun X; Yuan Y; Liu H; Li T; Zhao Y; Kang C; Wu X
Cancer Res; 2021 Dec; 81(23):5876-5888. PubMed ID: 34670781
[TBL] [Abstract][Full Text] [Related]
8. ALKBH5 Modulates Asthma Progression by Downregulating N6-methyladenosine Methylation.
Fan X; Wei C; Han Y
Iran J Allergy Asthma Immunol; 2024 Apr; 23(2):211-219. PubMed ID: 38822515
[TBL] [Abstract][Full Text] [Related]
9. Pan-Cancer Analysis Shows That ALKBH5 Is a Potential Prognostic and Immunotherapeutic Biomarker for Multiple Cancer Types Including Gliomas.
Wei C; Wang B; Peng D; Zhang X; Li Z; Luo L; He Y; Liang H; Du X; Li S; Zhang S; Zhang Z; Han L; Zhang J
Front Immunol; 2022; 13():849592. PubMed ID: 35444654
[TBL] [Abstract][Full Text] [Related]
10. A positive-feedback loop between HBx and ALKBH5 promotes hepatocellular carcinogenesis.
Qu S; Jin L; Huang H; Lin J; Gao W; Zeng Z
BMC Cancer; 2021 Jun; 21(1):686. PubMed ID: 34112124
[TBL] [Abstract][Full Text] [Related]
11. The N6-Methyladenosine Regulator
Zhao Y; Sun J; Jin L
Int J Mol Sci; 2022 Dec; 23(24):. PubMed ID: 36555463
[TBL] [Abstract][Full Text] [Related]
12. The m6A demethylase ALKBH5 promotes tumor progression by inhibiting RIG-I expression and interferon alpha production through the IKKε/TBK1/IRF3 pathway in head and neck squamous cell carcinoma.
Jin S; Li M; Chang H; Wang R; Zhang Z; Zhang J; He Y; Ma H
Mol Cancer; 2022 Apr; 21(1):97. PubMed ID: 35395767
[TBL] [Abstract][Full Text] [Related]
13. ZWINT: A potential therapeutic biomarker in patients with glioblastoma correlates with cell proliferation and invasion.
Yang L; Han N; Zhang X; Zhou Y; Chen R; Zhang M
Oncol Rep; 2020 Jun; 43(6):1831-1844. PubMed ID: 32323832
[TBL] [Abstract][Full Text] [Related]
14. Circ_0005615 enhances multiple myeloma progression through interaction with EIF4A3 to regulate MAP3K4 m6A modification mediated by ALKBH5.
Zhu K; Gou F; Zhao Z; Xu K; Song J; Jiang H; Zhang F; Yang Y; Li J
Leuk Res; 2024 Jun; 141():107451. PubMed ID: 38663164
[TBL] [Abstract][Full Text] [Related]
15. 3D proteome-wide scale screening and activity evaluation of a new ALKBH5 inhibitor in U87 glioblastoma cell line.
Malacrida A; Rivara M; Di Domizio A; Cislaghi G; Miloso M; Zuliani V; Nicolini G
Bioorg Med Chem; 2020 Feb; 28(4):115300. PubMed ID: 31937477
[TBL] [Abstract][Full Text] [Related]
16. Dexamethasone-mediated oncogenicity in vitro and in an animal model of glioblastoma.
Luedi MM; Singh SK; Mosley JC; Hassan ISA; Hatami M; Gumin J; Andereggen L; Sulman EP; Lang FF; Stueber F; Fuller GN; Colen RR; Zinn PO
J Neurosurg; 2018 Dec; 129(6):1446-1455. PubMed ID: 29328002
[TBL] [Abstract][Full Text] [Related]
17. ALKBH5 promotes non-small cell lung cancer progression and susceptibility to anti-PD-L1 therapy by modulating interactions between tumor and macrophages.
Hua X; Xu Q; Wu R; Sun W; Gu Y; Zhu S; Liu X; Lv T; Song Y
J Exp Clin Cancer Res; 2024 Jun; 43(1):164. PubMed ID: 38872221
[TBL] [Abstract][Full Text] [Related]
18. ALKBH5 suppresses malignancy of hepatocellular carcinoma via m
Chen Y; Zhao Y; Chen J; Peng C; Zhang Y; Tong R; Cheng Q; Yang B; Feng X; Lu Y; Xie H; Zhou L; Wu J; Zheng S
Mol Cancer; 2020 Aug; 19(1):123. PubMed ID: 32772918
[TBL] [Abstract][Full Text] [Related]
19. m
Nagaki Y; Motoyama S; Yamaguchi T; Hoshizaki M; Sato Y; Sato T; Koizumi Y; Wakita A; Kawakita Y; Imai K; Nanjo H; Watanabe H; Imai Y; Minamiya Y; Kuba K
Genes Cells; 2020 Aug; 25(8):547-561. PubMed ID: 32449584
[TBL] [Abstract][Full Text] [Related]
20. Promoting axon regeneration by inhibiting RNA N6-methyladenosine demethylase ALKBH5.
Wang D; Zheng T; Zhou S; Liu M; Liu Y; Gu X; Mao S; Yu B
Elife; 2023 Aug; 12():. PubMed ID: 37535403
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
